Editorial Staff

  • Executive Editor/VP-Special Projects:
    Jeff Hall
  • Senior Editor
    Brian McCurdy
  • Circulation and Subscriptions
    Bonnie Shannon
  • Art Director:
    Alana Balboni
  • Editorial Correspondence

  • Jeff Hall, Executive Editor/VP-Special Projects, Podiatry Today
  • HMP Communications, 83 General Warren Blvd
    Suite 100, Malvern PA 19355
  • Telephone: (800) 237-7285, ext. 214
    Fax: (610) 560-0501
  • Email: jhall@hmpcommunications.com
  • September 2004 | Volume 17 - Issue 9
    DPM-Aire says its XJ-3000C can rid the air of harmful bacteria and mycotic nail dust.

    5,240 reads | 0 comments | 09/03/08
    With so many people dealing with dry skin and nail diseases, one cannot have too many options for treatment. That is why you may want to consider adding two new products to your armamentarium. Keralac® Lotion is a 35% urea-based moisturizer manufactured by Doak Dermatologics. Offering ingredients of vitamin E, lactic acid and zinc, Keralac Lotion can promote a favorable pH level, which can increase healing and protect against harmful bacteria, according to the company. Available in 7-ounce and 11-ounce bottles, Keralac Lotion has a light texture and patients can spread it eas... continue reading
    If chronic venous insufficiency (CVI) is allowed to continue, inflammation will develop (as shown above). According to the author, there is an increasing incidence of CVI with the continued aging of the population.
    By Michael Baker, DPM, CWS
    8,750 reads | 0 comments | 09/03/08
    As foot and ankle surgeons, we are constantly reminded that we are the ultimate champions of diabetic foot care. However, another emerging problem is chronic venous insufficiency (CVI) ulcerations. While it does not have nearly the potential impact of limb loss one may see with complications from the diabetic foot, there is an increasing incidence of CVI with the continued aging of the population. According to current estimates, CVI affects between 0.1 and 0.3 percent of the total population in the United States. The healthcare industry spends $400 million annually on treating CVI. Unlike th... continue reading